Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679 |
Resumo: | Introduction: Super-refractory status epilepticus is defined as status epilepticus that persists or recurs 24 hours after anaesthetic therapy onset or after its withdrawal. It is mostly found in intensive care units and carries high mortality but good long-term prognosis for those who survive. In contrast with the initial phases of status epilepticus, treatment lacks strong scientific evidence and is mostly derived from case reports or small case series.Objective: To propose a protocol for the treatment of super-refractory status epilepticus in level III intensive care units, focusing on the treatment strategies to control clinical and/or electroencephalographic epileptic activity.Material and Methods: Narrative review of the literature by PubMed search. Available evidence was discussed in consensus meetings by intensive care and neurology experts’ from a level III intensive care unit and one of the Portuguese reference centres for the treatment of refractory epilepsy, respectively.Results: Anaesthetics with the highest level of evidence are propofol, midazolam, thiopental and ketamine. These represent the basis of the treatment of super-refractory status epilepticus and should be used in combination with antiepileptic drugs. The level of evidence for the latter is lower, however, levetiracetam, topiramate, pregabalin, lacosamide, valproic acid, phenytoin and perampanel may be recommended. Alternative therapeutic strategies with very low level of evidence are recommended in cases of total absence of clinical response, such as magnesium sulphate, pyridoxine, ketogenic diet, therapeutic hypothermia and immunosupression.Conclusion: We propose a treatment protocol based on a sequential combination of anaesthetics, anti-epileptic drugs and alternative therapies. Strategies to evaluate treatment response and to wean drugs based on clinical results are also proposed. |
id |
RCAP_771b1521851cb9af70761d0b1607627b |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/9679 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Consensus Protocol for the Treatment of Super-Refractory Status EpilepticusProtocolo de Consenso para o Tratamento do Estado de Mal Epiléptico Super-RefractárioClinical ProtocolsConsensusCritical CareReview LiteratureStatus EpilepticusConsensoCuidados CríticosMal EpilépticoProtocolos ClínicosRevisão da LiteraturaIntroduction: Super-refractory status epilepticus is defined as status epilepticus that persists or recurs 24 hours after anaesthetic therapy onset or after its withdrawal. It is mostly found in intensive care units and carries high mortality but good long-term prognosis for those who survive. In contrast with the initial phases of status epilepticus, treatment lacks strong scientific evidence and is mostly derived from case reports or small case series.Objective: To propose a protocol for the treatment of super-refractory status epilepticus in level III intensive care units, focusing on the treatment strategies to control clinical and/or electroencephalographic epileptic activity.Material and Methods: Narrative review of the literature by PubMed search. Available evidence was discussed in consensus meetings by intensive care and neurology experts’ from a level III intensive care unit and one of the Portuguese reference centres for the treatment of refractory epilepsy, respectively.Results: Anaesthetics with the highest level of evidence are propofol, midazolam, thiopental and ketamine. These represent the basis of the treatment of super-refractory status epilepticus and should be used in combination with antiepileptic drugs. The level of evidence for the latter is lower, however, levetiracetam, topiramate, pregabalin, lacosamide, valproic acid, phenytoin and perampanel may be recommended. Alternative therapeutic strategies with very low level of evidence are recommended in cases of total absence of clinical response, such as magnesium sulphate, pyridoxine, ketogenic diet, therapeutic hypothermia and immunosupression.Conclusion: We propose a treatment protocol based on a sequential combination of anaesthetics, anti-epileptic drugs and alternative therapies. Strategies to evaluate treatment response and to wean drugs based on clinical results are also proposed.Introdução: O estado de mal epiléptico super-refractário define-se como um estado de mal epiléptico que persiste ou recorre 24 horas após o início da terapêutica anestésica ou após a sua suspensão. Encontra-se fundamentalmente em unidades de cuidados intensivos e está associado a uma elevada mortalidade apesar de ter um bom prognóstico a longo prazo nos doentes que sobrevivem. Ao contrário das fases iniciais do estado de mal epiléptico, o tratamento não é baseado numa forte evidência científica e deriva principalmente de relatos ou pequenas séries de casos.Objectivo: Propor um protocolo de tratamento do estado de mal epiléptico super-refractário em unidades de cuidados intensivos de nível III, focando-se nas estratégias de tratamento para controlar a actividade epiléptica clínica e/ou electroencefalográfica.Material e Métodos: Revisão narrativa da literatura no PubMed, seguida de discussão em reuniões de consenso de peritos de medicina intensiva e neurologia de uma unidade de cuidados intensivos de nível III e de um dos centros de referência para o tratamento daepilepsia refractária em Portugal, respectivamente.Resultados: Os fármacos anestésicos com maior nível de evidência são o propofol, midazolam, tiopental e ketamina. Estes representam a base do tratamento do estado de mal super-refractário e devem ser utilizados em combinação com fármacos antiepilépticos. O nível de evidência para estes últimos é menor, contudo, podem ser recomendados o levetiracetam, topiramato, pregabalina, lacosamida, perampanel, ácido valpróico, fenitoína e perampanel. São recomendadas estratégias terapêuticas alternativas com muito baixo nível de evidência, em casos de ausência total de resposta clínica, tais como o sulfato de magnésio, piridoxina, dieta cetogénica, hipotermia terapêutica e imunossupressão.Conclusão: Propomos um protocolo de tratamento baseado numa combinação sequencial de fármacos anestésicos, antiepilépticos e terapêuticas alternativas. São também propostas estratégias de avaliação da eficácia da terapêutica e de desmame farmacológico progressivo de acordo com a resposta clínica obtida.Ordem dos Médicos2018-10-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfimage/jpegapplication/pdfapplication/pdfapplication/mswordapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679oai:ojs.www.actamedicaportuguesa.com:article/9679Acta Médica Portuguesa; Vol. 31 No. 10 (2018): October; 598-605Acta Médica Portuguesa; Vol. 31 N.º 10 (2018): Outubro; 598-6051646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/5526https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/9796https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/9805https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/9806https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/10396https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/10427Direitos de Autor (c) 2018 Acta Médica Portuguesainfo:eu-repo/semantics/openAccessGomes, DanielPimentel, JoséBentes, CarlaAguiar de Sousa, DianaAntunes, Ana PatríciaAlvarez, AntónioSilva, Zélia Costa e2022-12-20T11:05:47Zoai:ojs.www.actamedicaportuguesa.com:article/9679Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:19:44.377323Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus Protocolo de Consenso para o Tratamento do Estado de Mal Epiléptico Super-Refractário |
title |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus |
spellingShingle |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus Gomes, Daniel Clinical Protocols Consensus Critical Care Review Literature Status Epilepticus Consenso Cuidados Críticos Mal Epiléptico Protocolos Clínicos Revisão da Literatura |
title_short |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus |
title_full |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus |
title_fullStr |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus |
title_full_unstemmed |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus |
title_sort |
Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus |
author |
Gomes, Daniel |
author_facet |
Gomes, Daniel Pimentel, José Bentes, Carla Aguiar de Sousa, Diana Antunes, Ana Patrícia Alvarez, António Silva, Zélia Costa e |
author_role |
author |
author2 |
Pimentel, José Bentes, Carla Aguiar de Sousa, Diana Antunes, Ana Patrícia Alvarez, António Silva, Zélia Costa e |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Gomes, Daniel Pimentel, José Bentes, Carla Aguiar de Sousa, Diana Antunes, Ana Patrícia Alvarez, António Silva, Zélia Costa e |
dc.subject.por.fl_str_mv |
Clinical Protocols Consensus Critical Care Review Literature Status Epilepticus Consenso Cuidados Críticos Mal Epiléptico Protocolos Clínicos Revisão da Literatura |
topic |
Clinical Protocols Consensus Critical Care Review Literature Status Epilepticus Consenso Cuidados Críticos Mal Epiléptico Protocolos Clínicos Revisão da Literatura |
description |
Introduction: Super-refractory status epilepticus is defined as status epilepticus that persists or recurs 24 hours after anaesthetic therapy onset or after its withdrawal. It is mostly found in intensive care units and carries high mortality but good long-term prognosis for those who survive. In contrast with the initial phases of status epilepticus, treatment lacks strong scientific evidence and is mostly derived from case reports or small case series.Objective: To propose a protocol for the treatment of super-refractory status epilepticus in level III intensive care units, focusing on the treatment strategies to control clinical and/or electroencephalographic epileptic activity.Material and Methods: Narrative review of the literature by PubMed search. Available evidence was discussed in consensus meetings by intensive care and neurology experts’ from a level III intensive care unit and one of the Portuguese reference centres for the treatment of refractory epilepsy, respectively.Results: Anaesthetics with the highest level of evidence are propofol, midazolam, thiopental and ketamine. These represent the basis of the treatment of super-refractory status epilepticus and should be used in combination with antiepileptic drugs. The level of evidence for the latter is lower, however, levetiracetam, topiramate, pregabalin, lacosamide, valproic acid, phenytoin and perampanel may be recommended. Alternative therapeutic strategies with very low level of evidence are recommended in cases of total absence of clinical response, such as magnesium sulphate, pyridoxine, ketogenic diet, therapeutic hypothermia and immunosupression.Conclusion: We propose a treatment protocol based on a sequential combination of anaesthetics, anti-epileptic drugs and alternative therapies. Strategies to evaluate treatment response and to wean drugs based on clinical results are also proposed. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-10-31 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679 oai:ojs.www.actamedicaportuguesa.com:article/9679 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/9679 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/5526 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/9796 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/9805 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/9806 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/10396 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9679/10427 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2018 Acta Médica Portuguesa info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2018 Acta Médica Portuguesa |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf image/jpeg application/pdf application/pdf application/msword application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 31 No. 10 (2018): October; 598-605 Acta Médica Portuguesa; Vol. 31 N.º 10 (2018): Outubro; 598-605 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817550117487509504 |